DNA

Oncocyte’s VitaGraftTM Kidney Identifies Transplant Rejection 10 Months Earlier

Interventional study compares VitaGraft to current transplant rejection monitoring protocolsOncocyte's VitaGraft assay detects antibody-mediated transplant rejection 10 months sooner than…

9 months ago

Myriad Genetics and Leading Cancer Center Collaborate to Study the Use of Minimal Residual Disease Testing in Breast Cancer

Research will use Myriad’s high-definition MRD testing platform based on whole-genome sequencingSALT LAKE CITY, Sept. 18, 2023 (GLOBE NEWSWIRE) --…

9 months ago

Applied DNA Partners with Cornell University College of Veterinary Medicine to Accelerate Development of Veterinary Vaccine Platform Targeting Diseases that Impact High-Value Animals

Agreement Focuses on the Accelerated Development of LNP-encapsulated LineaDNA™ Vaccines to Eliminate the Use of Plasmid DNA and Reduce the…

10 months ago

Falsification Rate of Telemedicine-Based Urine Drug Screenings are On-Par With In-Person Treatment Programs, New Bicycle Health Study Finds

Less than 3% of study participants receiving medication for opioid use disorder via telehealth falsified urine drug screening results; just…

10 months ago

Evoke Pharma Receives Notice of Allowance from USPTO for GIMOTI®

SOLANA BEACH, Calif., Sept. 14, 2023 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused primarily on…

10 months ago

Nemaura Medical Provides Update on Nasdaq Compliance Status and Process

LOUGHBOROUGH, Sept. 14, 2023 (GLOBE NEWSWIRE) -- Nemaura Medical, Inc.(Nasdaq: NMRD) (“Nemaura” or the “Company”), a medical technology company focused…

10 months ago

Genelux Corporation Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

WESTLAKE VILLAGE, Calif., Sept. 14, 2023 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced…

10 months ago

23andMe and Sickle Cell 101 Collaborate to Expand Sickle Cell Awareness Program

23andMe will offer its Health + Ancestry Service at no cost for up to 1,000 eligible* participants who are 18…

10 months ago

IMUNON Reminds Investors of its Virtual R&D Day Tomorrow at 4:00 p.m. ET

Program will feature executive management plus key opinion leaders in immuno-oncology and vaccine development LAWRENCEVILLE, N.J., Sept. 13, 2023 (GLOBE…

10 months ago